nir-vana innovation network

The company has developed an approach that provides life science partners with the opportunity to work with high-quality and reliable targets or antigens, compatible with all applications and in all areas (human, animal and plant).
This includes developing antibodies and/or discovering drug candidates through structure-based drug design (X-ray and Cryogenic electron microscopy) or high-throughput screening assays.
The platform developed by the company also enables the formulation of new vaccines including against COVID-19.

The company is willing to further develop its technology by participating in a European call for proposal.
The following topics have been identified but the company is open to other topics where its technology could be useful:
- HORIZON-HLTH-2021-STAYHLTH-01-02 : ”Towards a molecular and neurobiological understanding of mental health and mental illness for the benefit of citizens and patients”
- HORIZON-HLTH-2022-DISEASE-06-02-two-stage : “Pre-clinical development of the next generation of immunotherapies for diseases or disorders with unmet medical needs”
- HORIZON-HLTH-2022-DISEASE-06-03-two-stage “Vaccines 2.0 – Developing the next generation of vaccines”
- HORIZON-HLTH-2022-DISEASE-06-04-two-stage “Development of new effective therapies for rare diseases”

Research or Technical cooperation agreement would be concluded between the French SME and academic partners

Advantages & innovations

Preparing high quality therapeutic targets for making the best drugs is a challenge tackled by only a few contract research organisations. Membrane proteins represents more than 60% of the market. The company's major advantage is to be able to prepare all types of targets (G protein-coupled receptors -GPCR, ion channels, receptors, transporters and viral targets) for all markers (human, animal, crop science). This very specific approach gives access to a bigger market whereas other players work mainly on GPCRs (<30% of the market). Moreover, the platform developed by the company allows the preparation of fully native targets without modification of their primary structure, where other players mutate and truncate the targets to help their stabilization. The company owns 8 patent families and has been involved in 28 international papers.

Stage of development

Already on the market

Partner sought

The SME is looking for academics and R&D institutions involved in target identification and membrane target validation (G protein-coupled receptors, ion channels, receptors, transporters and viral targets) in all therapeutic areas (oncology, Central nervous system diseases, cardiovascular diseases, infectious diseases, ....) and for all life science fields (human, animal, crop science). Ideally partner sought is participating or piloting a Horizon Europe proposal and open to work with new partners. Research cooperation or technical ccoperation agreement would drive the collaboration.